Cara Therapeutics (CARA) Reports In-Line Q3 EPS

Cara Therapeutics (NASDAQ: CARA) reported Q3 EPS of ($0.52), in-line with the analyst estimate of ($0.52). Revenue for the quarter came in at $4.87 million versus the consensus estimate of $9.95 million.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Plains GP Holdings (PAGP) Misses Q2 EPS by 6c
• Atlassian results seen as 'game changer' for AI kills software worries
• Soligenix, Inc. (SNGX) Tops Q2 EPS by 8c